Author | Stephen M. Ansell, MD, PhD

Articles

The Era of Immuno-Oncology: Are We There Yet?

March 15, 2015

The next few years hold great promise, as new agents emerge and others consolidate their place on our shelves. We will be forced to rethink strategies and redefine management as a new era of immuno-oncology dawns.

Innate Immune B Cells Gone Bad

November 15, 2011

Normal B lymphocytes can follow either of two functionally distinct pathways of development. The first is a classical germinal center T-dependent pathway in which diversification and maturation generate a delayed but almost unlimited high-affinity response to antigens.